

Volume 31 (Supplement 1) May 2004

30th
ANNIVERSARY

1974 • 2004

THE CANADIAN JOURNAL OF

Neurological Sciences

LE JOURNAL CANADIEN DES

Sciences Neurologiques

AN INTERNATIONAL JOURNAL / UN JOURNAL INTERNATIONAL

39th MEETING OF THE
CANADIAN CONGRESS OF
NEUROLOGICAL SCIENCES




CCNS • CCSN
June 8-12 juin 2004

ABSTRACTS

The official Journal of: The Canadian Neurological Society, The Canadian Neurosurgical Society,
The Canadian Society of Clinical Neurophysiologists, The Canadian Association of Child Neurology

REMINYL:^{*} FOR THE TREATMENT OF ALZHEIMER'S DISEASE

†† Now on provincial
formularies for
Ontario, Quebec, Alberta,
Saskatchewan, Manitoba,
New Brunswick, Nova Scotia
and Newfoundland



Unique proposed mode of action:

Cholinesterase inhibition
and nicotinic modulation^{1,2†}

New REMINYL:
The difference may be
nicotinic modulation[†]

More than just cholinesterase inhibition,
REMINYL enhances the action of
acetylcholine through binding to an
allosteric site on the nicotinic receptors^{1,2†}



† Based on *in vitro* data. The clinical relevance to humans is unknown. The majority of common side effects occurred during the dose-escalation period and were primarily gastrointestinal. During maintenance therapy, the most common side effects were: REMINYL 16 mg/day-nausea (4%) and diarrhea (5%); REMINYL 24 mg/day-nausea (6%), vomiting (6%) and anorexia (5%).

REMINYL (galantamine hydrobromide) is indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer's type. REMINYL has not been studied in controlled clinical trials for longer than 6 months. There is no evidence that galantamine alters the course of the underlying dementing process.

References:

1. REMINYL[®] (galantamine hydrobromide) Product Monograph, JANSSEN-ORTHO Inc., October 29, 2003.
2. Maelicke A, Albuquerque EX. *Eur J Pharmacol* 2000;393:165-170.

†† Exception drug status


RMJA041001A  



JANSSEN-ORTHO Inc.
19 Green Belt Drive,
Toronto, ON M3C 1L9
www.janssen-ortho.com

© 2004 JANSSEN-ORTHO Inc.

* All trademark rights used under license 7955

 **Reminyl**^{*}
Galantamine hydrobromide tablets

Think Cognition